KasralainiH
Cairo, 11956, Egypt
NCT Number: NCT03239964
Two groups of patients (73 patients each) undergoing routine caesarean section has recurrent keloid at site of surgical scar. One group will undergo surgical excision of keloid. The other group will have combined surgical excision of keloid and single intralesional dexamethasone injection at edges of wound.All patients were reviewed once per month for 6 months for evidence of recurrence
Looking for future studies?
Notify Me20 year–45 year
Female
Interventional
Phase 4
Cairo, 11956, Egypt
One hundred forty six patients that are admitted at Kasr Al Aini teaching university hospital for caesarean section, will be enrolled in this randomized clinical trial after approval by the local ethical health committee. A written informed consent will be obtained from each participant after full explanation of the procedure.
Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of the keloid is performed and minimal undermining followed by the usual steps of caesarean section. Primary closure of the wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. In 73 patients (group B), the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
For all patients, the wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.
Postoperative medications are given to all patients in the form of analgesics and antibiotics as routinely given at the hospital. All patients were advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) were used in any of the patients. All patients were reviewed once per month for 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
total extralesional surgical excision of the keloid is performed and minimal undermining
Time frame: 6 months
same/smaller/larger than pretreatment lesion
Time frame: 6 months
itching sensation at the site of wound
Time frame: 6 months
redness or coloured pigmentation at wound site
Time frame: 6 months
feel burn at wound site
Time frame: 6 months
area of gaping of wound that requires secondary sutures
Time frame: 6 months
area of gaping of wound that requires frequent dressings only
Kasr El Aini Hospital
Other
Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07673484
Allergic Contact Dermatitis, Cicatrix
Küçükçekmece, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07420166
Cicatrix, Collagen Diseases
Bahawalpur, Punjab Province, Pakistan
View Trial DetailsNCT07263100
Cicatrix, Cicatrix, Hypertrophic
Sattahip, Changwat Chon Buri, Thailand
View Trial DetailsNCT05330078
Cicatrix, Collagen Diseases
San Diego, California, United States
View Trial Details